MY160392A - Triptolide prodrugs - Google Patents

Triptolide prodrugs

Info

Publication number
MY160392A
MY160392A MYPI2011005335A MYPI2011005335A MY160392A MY 160392 A MY160392 A MY 160392A MY PI2011005335 A MYPI2011005335 A MY PI2011005335A MY PI2011005335 A MYPI2011005335 A MY PI2011005335A MY 160392 A MY160392 A MY 160392A
Authority
MY
Malaysia
Prior art keywords
formula
compounds
triptolide prodrugs
triptolide
prodrugs
Prior art date
Application number
MYPI2011005335A
Inventor
Ingrid Gunda Georg
Satish Prakash Patil
Ashok K Saluja
Rohit Chugh
Selwyn M Vickers
Original Assignee
Univ Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minnesota filed Critical Univ Minnesota
Publication of MY160392A publication Critical patent/MY160392A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

THE INVENTION PROVIDES COMPOUNDS OF FORMULA I: OR A SALT THEREOF. THE INVENTION ALSO PROVIDES PHARMACEUTICAL COMPOSITIONS COMPRISING A COMPOUND OF FORMULA I, PROCESSES FOR PREPARING COMPOUNDS OF FORMULA I, INTERMEDIATES USEFUL FOR PREPARING COMPOUNDS OF FORMULA I AND THERAPEUTIC METHODS USING THE COMPOUNDS OF FORMULA I.
MYPI2011005335A 2009-05-07 2010-05-07 Triptolide prodrugs MY160392A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17624909P 2009-05-07 2009-05-07

Publications (1)

Publication Number Publication Date
MY160392A true MY160392A (en) 2017-03-15

Family

ID=42244313

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2011005335A MY160392A (en) 2009-05-07 2010-05-07 Triptolide prodrugs

Country Status (17)

Country Link
US (1) US8507552B2 (en)
EP (1) EP2427467B1 (en)
JP (3) JP6000122B2 (en)
KR (1) KR101821823B1 (en)
CN (1) CN102596977B (en)
AU (1) AU2010245669B2 (en)
BR (1) BRPI1014802B8 (en)
CA (2) CA2760953C (en)
DK (1) DK2427467T3 (en)
EA (1) EA021135B1 (en)
ES (1) ES2552163T3 (en)
MX (1) MX2011011776A (en)
MY (1) MY160392A (en)
PL (1) PL2427467T3 (en)
PT (1) PT2427467E (en)
SG (1) SG175885A1 (en)
WO (1) WO2010129918A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9150600B2 (en) 2009-05-07 2015-10-06 Regents Of The University Of Minnesota Triptolide prodrugs
ES2902651T3 (en) * 2012-08-23 2022-03-29 Senestech Inc Reduction of the reproductive capacity of mammals
WO2014047783A1 (en) * 2012-09-25 2014-04-03 鼎泓国际投资（香港）有限公司 Pharmaceutical composition containing triptolide and triptolide derivative and bcl-2 inhibitor and use thereof
WO2014167581A2 (en) * 2013-04-01 2014-10-16 Laurus Labs Private Limited An improved process for the preparation of triptolide prodrugs
SG11201802915WA (en) * 2015-09-11 2018-05-30 Ys Ac Co Ltd Cancer treatment composition combining anti-cd26 antibody and other anticancer agent
CN109942665B (en) * 2018-04-02 2021-04-06 欣凯医药化工中间体（上海）有限公司 Triptolide derivative and preparation method and application thereof
CN110551171B (en) * 2018-05-31 2021-07-27 欣凯医药化工中间体（上海）有限公司 Preparation method of triptolide derivative
CA3112171A1 (en) * 2018-09-13 2020-03-19 Minneamrita Therapeutics, LLC Triptolide and prodrugs thereof for use in methods to treat fibrosis, nash, and nafld
WO2021221179A1 (en) * 2020-04-28 2021-11-04 国立大学法人高知大学 Establishment of mouse model using human pancreatic cancer organoid
EP4200022A1 (en) 2020-08-21 2023-06-28 Reyoung Corporation Triptolide conjugates and uses thereof
CN115227829B (en) * 2022-02-22 2023-10-13 成都中医药大学 Acid-sensitive aptamer triptolide conjugate and application thereof
AU2023435819A1 (en) 2023-03-09 2025-10-02 Minneamrita Therapeutics Llc Drug combination for treatment of pancreatic cancer
WO2024186319A1 (en) 2023-03-09 2024-09-12 Minneamrita Therapeutics Llc Drug combination for treatment of gastric cancer
AU2025207356A1 (en) 2024-01-11 2026-08-06 Minneamrita Therapeutics Llc Triptolide formulations

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843452A (en) 1992-11-09 1998-12-01 Pharmagenesis, Inc. Immunotherapy composition and method
US5759550A (en) 1993-05-06 1998-06-02 Pharmagenesis, Inc. Method for suppressing xenograft rejection
US5609991A (en) 1995-02-10 1997-03-11 Morton International, Inc. Photoimageable composition having improved alkaline process resistance and tack-free surface for contact imaging
US5663335A (en) 1996-03-01 1997-09-02 Pharmagenesis, Inc. Immunosuppressive compounds and methods
US5962516A (en) 1997-02-28 1999-10-05 Pharmagenesis, Inc. Immunosuppressive compounds and methods
US6204257B1 (en) * 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
US6548537B1 (en) * 1998-09-02 2003-04-15 Pharmagenesis, Inc. Triptolide prodrugs having high aqueous solubility
JP2002523495A (en) * 1998-09-02 2002-07-30 ファーマジェネシス， インコーポレイテッド Triptolide prodrug with high water solubility
WO2000048619A1 (en) 1999-02-16 2000-08-24 The Board Of Trustees Of The Leland Stanford Junior University Combined therapy of diterpenoid triepoxides and trail for synergistic killing of tumor cells
AU5368699A (en) 1999-04-16 2000-11-02 Chengdu Diao Pharmaceutical Group Company Limited Derivatives of triptolide, and preparation and uses thereof
US6294546B1 (en) 1999-08-30 2001-09-25 The Broad Of Trustees Of The Leland Stanford Junior University Uses of diterpenoid triepoxides as an anti-proliferative agent
US6620843B2 (en) 2001-01-19 2003-09-16 Pharmagenesis Anticancer treatment using triptolide prodrugs
EP1390358A4 (en) 2001-03-15 2004-06-16 Pharmagenesis Inc Amino acid derivatives of triptolide compounds as immune modulators and anticancer agent
KR101016969B1 (en) * 2001-12-21 2011-02-25 에이자이 아이엔씨. Process for preparing water-soluble phosphonooxymethyl derivatives of alcohols and phenols
AU2003243351B2 (en) 2002-05-31 2009-04-30 Pharmagenesis, Inc. Triptolide derivatives for modulation of apoptosis and immunosuppression
CN100398544C (en) * 2002-09-18 2008-07-02 成都达远药物有限公司 Water-soluble triptolide derivatives with high immunosuppressive activity and their application
WO2004058246A1 (en) 2002-12-17 2004-07-15 Pharmagenesis, Inc. Triptolide derivatives as immunomodulator and anticancer agents
CN1223595C (en) 2002-12-27 2005-10-19 中国科学院上海药物研究所 Triptolide alcohol derivative and its use
US6943259B2 (en) 2003-02-25 2005-09-13 Pharmagenesis, Inc. Halogenated triptolide derivatives as immunomodulators and anticancer agents
WO2005020887A2 (en) 2003-06-27 2005-03-10 Pharmagenesis, Inc. Method for treatment of severe acute respiratory syndrome
US7820834B2 (en) 2003-12-24 2010-10-26 Pharmagenesis, Inc. Triptolide 5,6-derivatives as immunomodulators and anticancer agents
JP5252765B2 (en) 2003-12-26 2013-07-31 学校法人東京薬科大学 Sebum production inhibitor, sebaceous gland development inhibitor, and skin external preparation
ES2385716T3 (en) 2004-03-02 2012-07-30 Pharmagenesis, Inc. Derivatives in the triptolide lactone ring as immunomodulators and anticancer agents
US20070244080A1 (en) 2004-06-25 2007-10-18 Pharmagenesis, Inc. Method for Treatment of Inflammatory Disorders Using Triptolide Compounds
WO2007025031A2 (en) * 2005-08-24 2007-03-01 Cephalon, Inc. Prodrugs of indanone and tetralone compounds
CN101049300A (en) 2006-04-04 2007-10-10 中国科学院上海药物研究所 Composition of medication containing lactone derivative of triperygium wilfordii, medicament form, and application
EP2079699A1 (en) * 2006-07-25 2009-07-22 Envivo Pharmaceuticals, Inc. Quinoline derivatives
CN101622263B (en) * 2007-03-06 2013-05-29 卫材R&D管理有限公司 Composition containing chloromethyl phosphate derivative with improved stability and preparation method thereof
FI20070574A0 (en) * 2007-07-30 2007-07-30 Kuopion Yliopisto Water-soluble ethylene phosphate prodrug of propofol
WO2009023201A1 (en) 2007-08-16 2009-02-19 Myelorx Llc Rigid derivatives of triptolide as anticancer, immune suppressant, anti-fibrosis, and cns protectant agents

Also Published As

Publication number Publication date
EP2427467B1 (en) 2015-08-05
MX2011011776A (en) 2012-08-03
BRPI1014802A2 (en) 2016-04-05
CA2760953C (en) 2017-05-30
ES2552163T3 (en) 2015-11-26
KR101821823B1 (en) 2018-01-24
EA201190293A1 (en) 2012-11-30
EA021135B1 (en) 2015-04-30
JP2016065099A (en) 2016-04-28
CN102596977B (en) 2016-06-29
EP2427467A1 (en) 2012-03-14
AU2010245669A1 (en) 2011-12-01
WO2010129918A8 (en) 2011-01-20
JP2014185181A (en) 2014-10-02
WO2010129918A1 (en) 2010-11-11
PT2427467E (en) 2015-11-19
AU2010245669B2 (en) 2015-11-26
PL2427467T3 (en) 2016-04-29
HK1168107A1 (en) 2012-12-21
KR20120015339A (en) 2012-02-21
JP2012526148A (en) 2012-10-25
JP6000122B2 (en) 2016-09-28
CN102596977A (en) 2012-07-18
SG175885A1 (en) 2011-12-29
US20120238529A1 (en) 2012-09-20
BRPI1014802B1 (en) 2020-09-24
US8507552B2 (en) 2013-08-13
CA2964631A1 (en) 2010-11-11
BRPI1014802B8 (en) 2021-05-25
DK2427467T3 (en) 2015-11-09
CA2760953A1 (en) 2010-11-11

Similar Documents

Publication Publication Date Title
MX2011011776A (en) Triptolide prodrugs.
MY148253A (en) Azaadamantane derivatives and methods of use
MX2014001595A (en) Indazole compounds, compositions and methods of use.
MX2010009752A (en) Oxadiazoanthracene compounds for the treatment of diabetes.
EA201170872A1 (en) PROTEINKINASE INHIBITORS
TN2012000248A1 (en) Novel spiropiperidine compounds
MY187718A (en) Pharmaceutical formulations
TN2012000152A1 (en) Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes
MY172924A (en) Neprilysin inhibitors
PH12014502733A1 (en) Neprilysin inhibitors
EP4219465A3 (en) Prmt5 inhibitors and uses thereof
TN2011000291A1 (en) Purine compounds
MX2010009646A (en) Antiviral therapeutic agents.
MY153958A (en) Lxr modulators
MX2013002851A (en) Inhibitors of notum pectinacetylesterase and methods of their use.
WO2013109972A3 (en) Therapeutic compounds
PH12014502492A1 (en) Pyrazole compounds as sglt1 inhibitors
IN2012DN05081A (en)
TN2019000038A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
IN2012DN02000A (en)
PH12013500051A1 (en) Crystalline form of a 3-phenoxymethylpyrrolidine compound
MX2010003056A (en) Valomaciclovir polymorphs.
GB2511240A (en) Nitrofurfuryl substituted phenyl linked piperidino-oxadiazoline conjugates as anti-tubercular agents and process for the preparation thereof
MX2013002656A (en) New process.
IN2012DN00346A (en)